Authors : Usha Topalkatti; Dr. Khachig K. Ishkhan; Ameer M Shazley

Volume/Issue : Volume 10 - 2025, Issue 7 - July

Google Scholar : https://tinyurl.com/usscd3sx

Scribd : https://tinyurl.com/586ywkun

DOI : https://doi.org/10.38124/ijisrt/25jul1733

Note : A published paper may take 4-5 working days from the publication date to appear in PlumX Metrics, Semantic Scholar, and ResearchGate.

Note : Google Scholar may take 30 to 40 days to display the article.

Abstract : Catastrophic antiphospholipid syndrome (CAPS) is an exceedingly rare (< 1 % of APS cases) but life-threatening variant of antiphospholipid syndrome, marked by rapid, widespread thrombosis that can precipitate myocardial infarction, stroke, and multiorgan failure. We report a 72-year-old south Asian woman with established cardiovascular risk factors—rest angina, hypertension, type 2 diabetes, hyperlipidaemia, and arthritis—who presented with acute right lower-limb ischemia manifesting as pain, pallor, and coolness. CT angiography revealed complete occlusion from the distal right common femoral artery into the crural vessels and severe stenosis of the left tibial and peroneal arteries. Despite emergent thrombectomy, thrombolysis, full anticoagulation, high-dose corticosteroids, and intravenous immunoglobulin (IVIG), clinical deterioration ensued, culminating in fatal multiorgan thrombosis. This case underscores the aggressive and often refractory nature of CAPS, where even prompt triple-therapy intervention may prove insufficient. Clinicians must balance the urgent need for anticoagulation against haemorrhagic risk, particularly in advanced ischemia or infarction. Mortality in CAPS was historically around 50%, though recent series report reductions to ~30–35% with early multimodal therapy Heightened awareness and rapid institution of anticoagulation combined with immunosuppression and vascular intervention remain critical to alter the otherwise dismal prognosis.

References :

1. Bernardi M, Spadafora L, Andaloro S, Piscitelli A, Fornaci G, Intonti C, Fratta AE, Hsu CE, Kaziròd-Wolski K, Metsovitis T, Biondi-Zoccai G, Sabouret P, Marzetti E, Cacciatore S. Management of Cardiovascular Complications in Antiphospholipid Syndrome: A Narrative Review with a Focus on Older Adults. J Clin Med. 2024 May 23;13(11):3064. doi: 10.3390/jcm13113064.
2. Cohen H, Cuadrado MJ, Erkan D, Duarte-Garcia A, Isenberg DA, Knight JS, Ortel TL, Rahman A, Salmon JE, Tektonidou MG, Williams DJ, Willis R, Woller SC, Andrade D. 16th International Congress on Antiphospholipid Antibodies Task Force Report on Antiphospholipid Syndrome Treatment Trends. Lupus. 2020 Oct;29(12):1571-1593. doi: 10.1177/0961203320950461.
3. Zhang J, Li C, Han X, Chen Z, Adhikari BK, Wang Y, Wang Y, Sun J. The digestive system involvement of antiphospholipid syndrome: pathophysiology, clinical characteristics, and treatment strategies. Ann Med. 2021 Dec;53(1):1328-1339. doi: 10.1080/07853890.2021.1962964.
4. Yang L, Guo R, Liu H, Chen B, Li C, Liu R, Liao S, Xie Q, Yin G. Mechanism of antiphospholipid antibody-mediated thrombosis in antiphospholipid syndrome. Front Immunol. 2025 Mar 13;16:1527554. doi: 10.3389/fimmu.2025.1527554.